查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1855054

前臨床成像的全球市場:各類型，各產品，各用途，各終端用戶，各流通管道，各地區 - 市場規模，產業趨勢，機會分析，預測(2025年～2033年)

Global Preclinical Imaging Market: By Type, Product, Application, End-User, Distribution Channel and By Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2025-2033
出版日期: | 出版商: Astute Analytica | 英文 232 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

臨床前影像市場經歷了強勁且持續的成長，2024 年市場規模約為 20.406 億美元。預計這一成長趨勢將持續，到 2033 年市場規模將達到約 33.322 億美元，2024 年至 2032 年的複合年增長率 (CAGR) 為 5.6%。這一增長反映了臨床前成像在藥物研發和生物醫學研究中日益增長的重要性。

推動這成長的因素很多。其中一個關鍵因素是，隨著製藥和生技公司尋求加速新療法的發現和審批，藥物研發的投資不斷增加。同時，對創新療法以滿足未被滿足的醫療需求的需求也在不斷增長，這進一步推動了對先進臨床前影像工具的需求。另一個關鍵因素是對非侵入性成像技術的日益重視。這些方法有助於減少對動物模型的依賴，最大限度地減少倫理問題，並降低研究成本。

市場動態

臨床前影像市場競爭激烈，成長強勁，這主要得益於藥物研發和生物醫學研究投資的不斷增加。布魯克、西門子醫療和珀金埃爾默等領先企業處於技術創新的前沿，它們利用戰略合作夥伴關係並整合人工智慧 (AI) 來推動成像技術的發展。這些領導者不斷開發涵蓋各種成像模式（包括 MRI、PET、CT 和光學成像）的複雜系統，以滿足研究人員不斷變化的需求。此類技術創新的一個顯著例子是 Levity 公司於 2025 年 9 月推出的 Living Image™ Synergy AI，這是一款專為體內成像研究人員設計的多模態分析軟體。

在臨床前影像市場，亞太地區已成為研發活動的關鍵中心，全球擴張仍是其重要的策略重點。 2024年，八家大型國際製藥公司在北京設立了新的研發機構，凸顯了該地區的重要性。在現有公司不斷擴大業務的同時，新的市場參與者也在湧現。例如，臨床前影像合約研究組織 (CRO) VeriSix 於2024年在巴黎推出了兩個早期研究平台。

主要成長驅動因素

對臨床前影像的持續需求正在推動研發管線的顯著擴張，從而創造了創紀錄的研究量。這一增長反映了對先進影像技術的日益依賴，以支持創新療法的開發。例如，到 2024 年，專注於複雜細胞和基因療法且需要體內追蹤的活躍臨床前計畫數量將超過 800 個。這些計畫凸顯了影像技術在監測前沿療法的體內行為和療效方面發揮的關鍵作用。

新興機會趨勢

隨著清除增強螢光斷層掃描 (CFT) 的應用，臨床前影像領域正在湧現一個強大的新前沿。這項創新成像技術獨特地彌合了整體動物光學成像和高解析度體外顯微鏡之間的差距，使研究人員能夠以前所未有的細節觀察生物過程。到 2024 年，至少有五家大型製藥公司已將 CFT 平台納入其藥物研發流程，尤其是在增強複雜生物製劑的生物分佈研究方面。 CFT 能夠以高達 4 微米的分辨率精確定位訊號，其成像能力比傳統光學方法精細幾個數量級。

優化障礙

不同研究機構和研究缺乏標準化的影像方案，這是阻礙臨床前影像市場成長的一大挑戰。影像技術、儀器設定和資料解讀方法的差異導致研究結果不一致，使得不同實驗室的結果難以比較和重現。這種不一致會削弱臨床前影像資料的可靠性和可信度，而這對於推進藥物研發和科學發現至關重要。

目錄

第1章 調查架構

  • 調查目的
  • 產品概要
  • 市場區隔

第2章 調查手法

  • 定性調查
    • 一次資訊·二次資訊
  • 定量調查
    • 一級資訊來源和二級資訊來源
  • 初步調查受訪者的各地區明細
  • 調查的前提
  • 市場規模·估計
  • 資料三角測量

第3章 摘要整理:前臨床成像的全球市場

第4章 前臨床成像的全球市場概要

  • 產業價值鏈分析
    • 原料供應商
    • 廠商
    • 經銷商
    • 終端用戶
  • 產業的展望
  • 大環境分析
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入廠商業者的威脅
    • 競爭的程度
  • 市場動態和趨勢
    • 成長促進因素
    • 阻礙因素
    • 機會
    • 主要趨勢
  • COVID-19對市場成長趨勢的影響評估
  • 市場成長與展望
    • 市場收益估計·預測, 2020-2033年
  • 競爭儀表板
    • 市場集中率
    • 企業佔有率分析(金額%)、2024年
    • 競爭製圖

第5章 前臨床成像的全球市場:各類型

  • 主要洞察
  • 市場規模及預測，2020年～2033年
    • 產品
    • 成像服務

第6章 前臨床成像的全球市場:各產品

  • 主要洞察
  • 市場規模及預測，2020年～2033年
    • CT成像
    • 光學成像
    • 超音波成像
    • MRI成像
    • PET/SPECT成像
    • 其他

第7章 前臨床成像的全球市場，各用途

  • 主要洞察
  • 市場規模及預測，2020年～2033年
    • 研究開發
    • 藥物研發

第8章 前臨床成像的全球市場:各終端用戶

  • 主要洞察
  • 市場規模及預測，2020年～2033年
    • 生物科技企業
    • 研究機關
    • 製藥公司

第9章 前臨床成像的全球市場:各流通管道

  • 主要洞察
  • 市場規模及預測，2020年～2033年
    • 線上
    • 離線

第10章 前臨床成像的全球市場:各地區

  • 主要洞察
  • 市場規模及預測，2020年～2033年
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲(MEA)
    • 南美

第11章 北美的前臨床成像市場分析

第12章 歐洲的前臨床成像市場分析

第13章 亞太地區的前臨床成像市場分析

第14章 中東·非洲的前臨床成像市場分析

第15章 南美的前臨床成像市場分析

第16章 企業簡介

  • Agilent Technologies
  • Bruker Corporation
  • Canon
  • Fujifilm Corporation
  • General Electric(GE)
  • Hitachi, Ltd.
  • Hologic
  • Konica Minolta, Inc.
  • Koninklijke Philips
  • Mediso Limited
  • MILabs B.V.
  • Molecubes
  • MR Solutions
  • PerkinElmer, Incorporated
  • Siemens Healthineers
  • TriFoil Imaging
  • Varex Imaging
  • Other Prominent Players
簡介目錄
Product Code: AA10251531

The preclinical imaging market is experiencing strong and sustained growth, with its value reaching approximately US$ 2,040.6 million in 2024. This upward trajectory is expected to continue, with projections indicating that the market will attain a valuation of around US$ 3,332.2 million by 2033. This represents a compound annual growth rate (CAGR) of 5.6% over the period from 2024 to 2032. Such growth reflects the increasing importance of preclinical imaging in the drug development process and biomedical research.

Several factors are driving this expansion. One of the primary contributors is the growing investment in drug development, as pharmaceutical and biotechnology companies seek to accelerate the discovery and approval of new therapeutics. Alongside this, there is a rising demand for innovative treatments to address unmet medical needs, which further fuels the need for sophisticated preclinical imaging tools. Another significant factor is the growing emphasis on non-invasive imaging techniques. These methods help reduce the reliance on animal models, minimizing ethical concerns and lowering research costs, which is increasingly important in modern biomedical research.

Noteworthy Market Developments

The preclinical imaging market is characterized by intense competition and robust growth, fueled by increasing investments in drug development and biomedical research. Leading companies such as Bruker, Siemens Healthineers, and PerkinElmer are at the forefront of innovation, leveraging strategic partnerships and integrating artificial intelligence (AI) to advance their imaging technologies. These major players are continuously developing sophisticated systems across various modalities, including MRI, PET, CT, and optical imaging, to meet the evolving needs of researchers. A notable example of such innovation occurred in September 2025, when Revvity, Inc. introduced its Living Image(TM) Synergy AI multimodal analysis software designed specifically for in vivo imaging researchers.

Global expansion remains a critical strategic focus within the preclinical imaging market, with the Asia-Pacific region emerging as a vital hub for research and development activities. In 2024, the significance of this region was underscored when eight major international pharmaceutical corporations established new R&D facilities in Beijing, reflecting the growing importance of Asia in the global pharmaceutical and biotechnology landscape. Alongside established companies expanding their presence, the market is also witnessing the entrance of new players. For instance, Verisix, a preclinical imaging contract research organization (CRO), was launched in Paris in 2024 with two initial research platforms.

Core Growth Drivers

The fundamental demand for preclinical imaging is driving a substantial expansion in research pipelines, which in turn is resulting in record-high volumes of studies being conducted. This growth reflects the increasing reliance on advanced imaging techniques to support the development of innovative therapies. For example, in 2024, the number of active preclinical programs focused on complex cell and gene therapies that require in vivo tracking exceeded 800. These programs highlight the critical role of imaging in monitoring the behavior and efficacy of cutting-edge treatments within living organisms.

Emerging Opportunity Trends

A powerful new opportunity in the preclinical imaging field is emerging with the adoption of clearing-enhanced fluorescence tomography (CFT). This innovative imaging modality uniquely bridges the gap between whole-animal optical imaging and high-resolution ex vivo microscopy, offering researchers the ability to visualize biological processes in unprecedented detail. In 2024, at least five major pharmaceutical companies incorporated CFT platforms into their drug discovery workflows, particularly to enhance biodistribution studies for complex biologics. By enabling precise three-dimensional localization of signals with resolutions as fine as 4 microns, CFT delivers an imaging capability that is an order of magnitude more detailed than traditional optical methods.

Barriers to Optimization

The lack of standardized imaging protocols across various research sites and studies presents a significant challenge that could impede the growth of the preclinical imaging market. Variability in imaging techniques, equipment settings, and data interpretation methods can lead to inconsistencies in research outcomes, making it difficult to compare or reproduce results across different laboratories. This inconsistency undermines the reliability and credibility of preclinical imaging data, which is critical for advancing drug development and scientific discovery.

Detailed Market Segmentation

By Type, the products segment continues to dominate the preclinical imaging market, holding a commanding share of 67.8%. This strong leadership position is largely driven by the ongoing development and introduction of innovative imaging systems and reagents that cater to the evolving needs of researchers. Companies operating in this space are consistently expanding their product portfolios, ensuring that they offer the latest technological advancements and a diverse range of solutions to meet increasing demand.

By Product, ultrasound imaging has firmly established itself as the leading product in the preclinical imaging market, securing a significant market share exceeding 25%. Its widespread adoption is largely attributable to its unique ability to provide real-time imaging, a feature that is indispensable in many preclinical research applications. This real-time capability allows researchers to observe biological processes as they happen, providing immediate feedback and detailed insights that static imaging techniques cannot offer.

By Application, the research and development (R&D) segment holds a commanding share of 58.9% of the revenue in the preclinical imaging market, underscoring the critical role that preclinical imaging plays in the study of complex diseases. This substantial share reflects the intense focus and investment in understanding the underlying mechanisms of various illnesses, which drives the demand for precise and advanced imaging technologies. Preclinical imaging has become an indispensable tool in modern drug discovery, offering researchers the ability to visualize disease progression in real time and evaluate the effectiveness of potential treatments at early stages.

By End Users, biotechnology companies have become the foremost end-users in the preclinical imaging market, commanding a significant 45.3% share of the total revenue. Their dominant position is largely attributed to the rapid expansion of the biotech sector, particularly in regions like North America and Asia-Pacific. This growth is fueled by increased investments, scientific advancements, and a surge in the development of innovative therapies, all of which drive a substantial need for advanced imaging technologies. These technologies are crucial for the detailed and precise evaluation of biological processes in the early stages of drug development.

Segment Breakdown

By Type

  • Products
  • Instruments
  • Reagents
  • Software Tools
  • Imaging Services

By Product

  • CT Imaging
  • Optical Imaging
  • Ultrasound Imaging
  • MRI Imaging
  • PET/SPECT Imaging
  • Others

By Application

  • Research and Development
  • Drug Discovery

By End User

  • Biotech Companies
  • Research Institutes
  • Pharmaceutical Companies

By Distribution Channel

  • Online
  • Offline

By Region

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America holds a commanding lead in the global preclinical imaging market, capturing a substantial 43.2% share. This dominant position results from a powerful combination of factors, including strong government funding, active venture capital investments, and extensive pharmaceutical research activities concentrated in the region. The U.S. National Institutes of Health (NIH) plays a pivotal role in this growth by awarding over 150 new grants in 2024 specifically for projects that require advanced in vivo imaging techniques. These grants significantly enhance research capabilities and drive innovation in preclinical imaging technologies.
  • In Canada, government support has also contributed to the region's prominence. The Canadian Foundation for Innovation (CFI) program made a major investment in 2024 by funding the acquisition of eight new high-field MRI systems at university research centers. This infrastructure upgrade strengthens the research ecosystem, enabling more sophisticated imaging studies and fostering scientific advancements in preclinical research. Complementing these developments, the U.S. Food and Drug Administration's (FDA) Animal Model Qualification Program approved three new imaging-based biomarkers for use in preclinical trials during 2024.

Leading Market Participants

  • Agilent Technologies
  • Bruker Corporation
  • Canon
  • Fujifilm Corporation
  • General Electric (GE)
  • Hitachi
  • Hologic
  • Konica Minolta, Inc.
  • Koninklijke Philips
  • Mediso Limited
  • MILabs B.V.
  • Molecubes
  • MR Solutions
  • PerkinElmer, Incorporated
  • Siemens Healthineers
  • TriFoil Imaging
  • Varex Imaging
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Preclinical Imaging Market

Chapter 4. Global Preclinical Imaging Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Raw material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Distributer
    • 4.1.4. End User
  • 4.2. Industry Outlook
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Opportunity
    • 4.5.4. Key Trends
  • 4.6. Covid-19 Impact Assessment on Market Growth Trend
  • 4.7. Market Growth and Outlook
    • 4.7.1. Market Revenue Estimates and Forecast (US$ Mn), 2020 - 2033
  • 4.8. Competition Dashboard
    • 4.8.1. Market Concentration Rate
    • 4.8.2. Company Market Share Analysis (Value %), 2024
    • 4.8.3. Competitor Mapping

Chapter 5. Global Preclinical Imaging Market, By Type

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 5.2.1. Products
      • 5.2.1.1. Instruments
      • 5.2.1.2. Reagents
      • 5.2.1.3. Software Tools
    • 5.2.2. Imaging Services

Chapter 6. Global Preclinical Imaging Market, By Product

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 6.2.1. CT Imaging
    • 6.2.2. Optical Imaging
    • 6.2.3. Ultrasound Imaging
    • 6.2.4. MRI Imaging
    • 6.2.5. PET/SPECT Imaging
    • 6.2.6. Others

Chapter 7. Global Preclinical Imaging Market, By Application

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 7.2.1. Research and Development
    • 7.2.2. Drug Discovery

Chapter 8. Global Preclinical Imaging Market, By End User

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 8.2.1. Biotech Companies
    • 8.2.2. Research Institutes
    • 8.2.3. Pharmaceutical Companies

Chapter 9. Global Preclinical Imaging Market, By Distribution Channel

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 9.2.1. Online
    • 9.2.2. Offline

Chapter 10. Global Preclinical Imaging Market, By Region

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 10.2.1. North America
      • 10.2.1.1. The U.S.
      • 10.2.1.2. Canada
      • 10.2.1.3. Mexico
    • 10.2.2. Europe
      • 10.2.2.1. Western Europe
        • 10.2.2.1.1. The UK
        • 10.2.2.1.2. Germany
        • 10.2.2.1.3. France
        • 10.2.2.1.4. Italy
        • 10.2.2.1.5. Spain
        • 10.2.2.1.6. Rest of Western Europe
      • 10.2.2.2. Eastern Europe
        • 10.2.2.2.1. Poland
        • 10.2.2.2.2. Russia
        • 10.2.2.2.3. Rest of Eastern Europe
    • 10.2.3. Asia Pacific
      • 10.2.3.1. China
      • 10.2.3.2. India
      • 10.2.3.3. Japan
      • 10.2.3.4. Australia & New Zealand
      • 10.2.3.5. ASEAN
      • 10.2.3.6. Rest of Asia Pacific
    • 10.2.4. Middle East & Africa (MEA)
      • 10.2.4.1. UAE
      • 10.2.4.2. Saudi Arabia
      • 10.2.4.3. South Africa
      • 10.2.4.4. Rest of MEA
    • 10.2.5. South America
      • 10.2.5.1. Brazil
      • 10.2.5.2. Argentina
      • 10.2.5.3. Rest of South America

Chapter 11. North America Preclinical Imaging Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 11.2.1. By Type
    • 11.2.2. By Product
    • 11.2.3. By Application
    • 11.2.4. By End User
    • 11.2.5. By Distribution Channel
    • 11.2.6. By Country

Chapter 12. Europe Preclinical Imaging Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 12.2.1. By Type
    • 12.2.2. By Product
    • 12.2.3. By Application
    • 12.2.4. By End User
    • 12.2.5. By Distribution Channel
    • 12.2.6. By Country

Chapter 13. Asia Pacific Preclinical Imaging Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 13.2.1. By Type
    • 13.2.2. By Product
    • 13.2.3. By Application
    • 13.2.4. By End User
    • 13.2.5. By Distribution Channel
    • 13.2.6. By Country

Chapter 14. Middle East & Africa Preclinical Imaging Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 14.2.1. By Type
    • 14.2.2. By Product
    • 14.2.3. By Application
    • 14.2.4. By End User
    • 14.2.5. By Distribution Channel
    • 14.2.6. By Country

Chapter 15. South America Preclinical Imaging Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020 - 2033 (US$ Mn)
    • 15.2.1. By Type
    • 15.2.2. By Product
    • 15.2.3. By Application
    • 15.2.4. By End User
    • 15.2.5. By Distribution Channel
    • 15.2.6. By Country

Chapter 16. Company Profile (Company Overview, Sales Composition Ratio, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 16.1. Agilent Technologies
  • 16.2. Bruker Corporation
  • 16.3. Canon
  • 16.4. Fujifilm Corporation
  • 16.5. General Electric (GE)
  • 16.6. Hitachi, Ltd.
  • 16.7. Hologic
  • 16.8. Konica Minolta, Inc.
  • 16.9. Koninklijke Philips
  • 16.10. Mediso Limited
  • 16.11. MILabs B.V.
  • 16.12. Molecubes
  • 16.13. MR Solutions
  • 16.14. PerkinElmer, Incorporated
  • 16.15. Siemens Healthineers
  • 16.16. TriFoil Imaging
  • 16.17. Varex Imaging
  • 16.18. Other Prominent Players